MSR1+巨噬细胞通过诱导ITM2A+CD4T细胞耗竭分化钝化抗肿瘤免疫
该研究基于TCGA和ICGC数据库筛选预后相关膜蛋白,发现HCC中ITM2A高表达提示预后良好且与免疫浸润相关。通过基因敲除小鼠模型和单细胞测序等方法,揭示MSR1+巨噬细胞通过破坏ITM2A-ZAP70轴诱导CD4T细胞耗竭,并构建靶向CD4的抗体药物偶联物ZEA-αCD4可抑制肿瘤生长并改善αPDL1疗效。
要点
- HCC中ITM2A高表达提示预后良好,与免疫细胞浸润丰富相关。
- MSR1+巨噬细胞通过破坏ITM2A-ZAP70轴诱导CD4T细胞耗竭分化。
- ZEA-αCD4靶向MSR1-ITM2A相互作用,激活抗肿瘤免疫并改善αPDL1疗效。
核心结论
- MSR1+巨噬细胞通过调控ITM2A-ZAP70轴促进肿瘤浸润ITM2A+CD4T细胞耗竭分化。
- ZEA-αCD4通过靶向MSR1-ITM2A相互作用激活抗肿瘤免疫并改善αPDL1免疫治疗疗效。
研究设计与样本
- 基于TCGA和ICGC数据库筛选预后相关膜蛋白。
- 构建全身基因、T细胞特异性或CD8T细胞特异性ITM2A敲除小鼠,用于原位移植或质粒来源的自发性肝细胞癌模型。
- 采用单细胞RNA测序、TimiGP分析、分子动力学模拟和生化实验探索MSR1-ITM2A-TCR信号调控轴的分子机制。
- 利用生物工程技术设计并构建新型CD4T靶向抗体药物偶联物。
主要发现
- HCC中ITM2A高表达提示预后更优,与肿瘤微环境中更丰富的免疫细胞浸润相关。
- 基因敲除小鼠HCC模型的单细胞RNA测序结果提示ITM2A影响肿瘤微环境中肿瘤浸润淋巴细胞的TCR信号,该推断在条件性ITM2A敲除小鼠中得到证实。
- MSR1+巨噬细胞在TCR激活过程中通过破坏ITM2A-ZAP70轴诱导CD4T细胞耗竭。
- ADC(ZEA-αCD4)治疗有效抑制肿瘤生长,且不依赖于经典αPDL1免疫治疗。
临床怎么用
- HCC中ITM2A高表达可作为预后良好的潜在生物标志物。
- 靶向MSR1-ITM2A相互作用(如ZEA-αCD4)可能激活抗肿瘤免疫并改善αPDL1免疫治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Immune-checkpoint inhibitors target the membrane protein; however, the role of membrane proteins in antitumor immunity remains poorly elucidated. In this study, we aimed to explore the role of membrane proteins and unearth potential membrane proteins that can be targeted. APPROACH AND RESULTS: We initially screened prognosis-related membrane proteins based on The Cancer Genome Atlas Program and International Cancer Genome Consortium databases. Whole-gene, T-cell-specific or CD8T-cell-specific integral membrane protein 2A (ITM2A) knockout mice were constructed and used for orthotopic transplantation or as plasmid-derived spontaneous hepatocellular carcinoma (HCC) models to explore the role of ITM2A in the tumor microenvironment (TME). Through single-cell RNA sequencing (scRNA-seq), TimiGP analysis, molecular dynamics simulations, and biochemical experiments, the molecular mechanisms underlying the MSR1-ITM2A-TCR signaling regulatory axis were explored. Finally, bioengineering technologies were used to design and construct a new CD4T-targeted antibody-drug conjugate (ADC).High ITM2A expression in HCC indicated a superior prognosis, which was associated with richer immune cell infiltration in the TME. The results of the scRNA-seq of the HCC model in genetically knocked-out mice suggest that ITM2A influences the TCR signaling of tumor-infiltrating lymphocytes in the TME. This inference was confirmed in conditional ITM2A knockout mice. MSR1 + macrophages induced CD4T exhaustion by disrupting the ITM2A-ZAP70 axis during TCR activation. ADC (ZEA-αCD4) treatment effectively inhibited tumor growth, independent of the classical αPDL1 immunotherapy. CONCLUSIONS: MSR1 + macrophages promote tumor-infiltrating ITM2A + CD4T exhaustion differentiation by regulating the ITM2A-ZAP70 axis. ZEA-αCD4 specifically targeted the MSR1-ITM2A interaction to activate antitumor immunity and improve the efficacy of αPDL1 immunotherapy.
引用
- Wang S, Wu P, Xu N, et al. MSR1 + macrophages passivate antitumor immunity by inducing ITM2A + CD4T exhaustion differentiation. Hepatology. 2025. PMID: 41104544. doi:10.1097/HEP.0000000000001578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。